NAD+ Protocol

Evidence Level: Emerging Evidence

Human and/or animal research exists and is accumulating, but the evidence base is not yet as extensive as an approved medicine.

Human evidence: Growing human trial base on NAD+ precursors and direct administration for metabolic and aging-biology endpoints, though optimal route/dose remains under study.

Animal evidence: Extensive rodent literature linking NAD+ decline to aging phenotypes.

Introduction & Mechanism of Action

Coenzyme studied for cellular-energy metabolism, DNA-repair signaling and aging-biology research.

Central redox coenzyme in mitochondrial energy production and a required cofactor for sirtuins and PARP enzymes involved in DNA repair; NAD+ levels decline with age, motivating research into supplementation or precursor loading.

Receptors/targets: Not receptor-mediated — acts as an enzyme cofactor

Areas of Research Interest

• Cellular-energy research
• DNA-repair pathway studies
• Aging-biology research

Benefits Reported in Research

• Cellular-energy research
• DNA-repair pathway studies
• Aging-biology research

Reported Research Dosing Range

The figures below are cited from published research literature and protocol references — they describe what has been studied, not a personal prescription or instruction.

Reported range: 50–100 mg

Reported frequency: 1× daily, subcutaneous

Reported cycle duration: 8–16 weeks

Escalation & maintenance: A dedicated weekly escalation and maintenance schedule specific to this peptide has not yet been published here — follow the dose range and frequency above, titrating conservatively from the low end, and consult a physician before adjusting.

Research Reference Data

Published research on NAD+ reports administration at 50–100 mg via subcutaneous route. The table below cites that published research — it is not an individualized instruction.

Reconstitution Reference

Published research protocols reconstitute a 100 mg vial with 2 mL bacteriostatic water, yielding a concentration of 50.00 mg/mL. This is cited reference information, not a personalized preparation instruction — use the general research calculator below for your own reference computation.

Research Protocol Timeline

A reference summary of how this compound is described across published research — formulation, reported administration, and reported cycle length.

Dilution Guide

Reconstitute with 2 mL bacteriostatic water

Bacteriostatic Water (BAC Water) is the only recommended diluent. Do not dilute with sterile water, normal saline, lidocaine, or any other solution unless explicitly specified by the manufacturer.

Handling Guide

General laboratory handling practice cited for reference — not a personalized instruction. Any human use should follow the guidance of a licensed physician.

Wash hands and clean the injection site with an alcohol swab. Pinch a fold of skin and insert the needle at a 45–90° angle for standard subcutaneous injection (abdomen, thigh, or upper arm). Inject slowly, withdraw, and apply gentle pressure. Rotate injection sites to reduce irritation, and dispose of needles in an approved sharps container.

Storage

Store lyophilized (powder) vials in a freezer at -20°C, protected from light. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within the timeframe recommended in your supplier documentation — typically 2–4 weeks.

Monitoring

Monitor for injection-site reactions and the side effects listed above. Stop use and consult a physician if severe or persistent reactions occur. This is a general monitoring guideline, not a personalized medical monitoring plan.

Side Effects

• Flushing
• Chest or abdominal tightness (particularly with rapid IV administration)
• Injection-site reaction
• Nausea

Contraindications

• Pregnancy
• Known hypersensitivity

Drug interactions

• Not well characterized in controlled human trials

Safety

• Rapid IV infusion associated with flushing, chest tightness and cramping in reported use
• Long-term optimal dosing not established

Optimal dosing, route and long-term outcomes remain under active study; most clinical benefit claims exceed current human evidence.

Expected Results & Comparison

NAD+, Epitalon, SS-31 and MOTS-C are all studied under the broad "longevity/mitochondrial" umbrella but via different mechanisms — NAD+ is a metabolic coenzyme, Epitalon is a bioregulator peptide with circadian/telomerase research interest, and SS-31/MOTS-C act more directly on mitochondrial membrane and signaling biology. None has established human evidence for extending lifespan.

References

Continue